Roger Meier

Part of Die Schweizerische Post AG, terreActive AG is a company that specializes in soar, security orchestration automation and response, ki, ai. The company is based in Aarau, Switzerland. terreActive was acquired by Die Schweizerische Post AG on July 04, 2023. The Swiss company's Security Operations Center is responsible for protecting the IT security infrastructure and preventing cyber attacks. The company was founded in 1996 by Marc-Yves Bächli, Roger Meier. Urs Rufer has been the CEO of the company since 1999.

Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland.

Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland.

Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland.

Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland.

Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland.

Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland.

Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland.

Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022.

Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022.

Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022.

Acthera Therapeutics AG is a Swiss biotechnology company that develops synthetic lipid membrane vesicles. The private company is based in Basel, Switzerland. The CEOs are Carlo Bertozzi, Pierre-Alain Monnard. The company was founded by Roger Meier.

Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022.

Acthera Therapeutics AG is a Swiss biotechnology company that develops synthetic lipid membrane vesicles. The private company is based in Basel, Switzerland. The CEOs are Carlo Bertozzi, Pierre-Alain Monnard. The company was founded by Roger Meier.

Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022.

Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022.